A translational research approach to poor treatment response in patients with schizophrenia: Clozapine-antipsychotic polypharmacy

Journal of Psychiatry and Neuroscience

Volumn 34, Issue 6, 2009, Pages 433-442

  Honer, William G ^a,b   Procyshyn, Ric M ^a,b   Chen, Eric Y H ^c   MacEwan, G William ^b   Barr, Alasdair M ^a,b  

^a BC Mental Health and Addictions Research Institute   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DONEPEZIL; FLUVOXAMINE; GALANTAMINE; HALOPERIDOL; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RACLOPRIDE; RISPERIDONE; SULPIRIDE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VOLINANSERIN; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; AMENORRHEA; ANTICHOLINERGIC SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG USE; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; GYNECOMASTIA; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LIBIDO DISORDER; LOW DRUG DOSE; MONOTHERAPY; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHOTOSENSITIVITY; POLYPHARMACY; PREPULSE INHIBITION; QT PROLONGATION; RETROGRADE EJACULATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; THERAPY DELAY; TRANQUILIZING ACTIVITY; WEIGHT GAIN;

EID: 70449574214     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Dougherty D, Conway PH. The "3T's" road map to transform US health care: the "how" of high-quality care. JAMA 2008;299:2319-2321 (Pubitemid 351724400)
2. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101. (Pubitemid 28026679)
3. Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopmine transmission in schizophrenia: relationship to illness phase. Biol Psychiatry 1999;46:56-72. (Pubitemid 29296818)
4. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-883 (Pubitemid 34020700)
5. Freedman R. Drug therapy: schizophrenia. N Engl J Med 2003;349:1738-1749
6. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610
7. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-526 (Pubitemid 32289814)
8. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262 (Pubitemid 34126903)
9. Procyshyn R, Honer WG, Wu TKY, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting. J Clin Psychiatry. In press.
10. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage policies. J Clin Psychiatry 1994;55:44-49 (Pubitemid 24081820)
11. Naber D, Holzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl 1992;(17):54-59
12. Paton C, Lelliott P, Harrington M, et al. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003;17:223-229 (Pubitemid 36753540)
13. Ganguly R, Kotzan JA, Miller S, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-1388
14. Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007;29:183-195
15. Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-339 (Pubitemid 32531565)
16. Procyshyn RM, Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 2004;37:12-17 (Pubitemid 38230735)
17. Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 2008;31:7-20.
18. Goff DC, Freudenreich O. Focus on polypharmacy in schizophrenia: Does anyone truly benefit? Int J Neuropsychopharmacol 2004;7:109-111 (Pubitemid 38823276)
19. Stahl SM. Focus on antipsychotic polypharmacy: Evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol 2004;7:113-116
20. Honer WG, Thornton AE, Sherwood M, et al. Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 2007;21:699-714. (Pubitemid 47294717)
21. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004;65:1597-1600
22. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-59 (Pubitemid 36043847)
23. Lee B, Walker V. Polypharmacy as the initial second-generation antipsychotic treatment. Psychiatr Serv 2008;59:717.
24. Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1071-1079 (Pubitemid 37464953)
25. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001;156:234-258
26. Braff DL, Swerdlow NR, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 1999;156:596-602.
27. Wiker C, Schilstrom B, Sandback C, et al. Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats. Int J Neuropsychopharmacol 2008;11:845-850
28. Eltayb A, Wadenberg ML, Schilstrom B, et al. Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride. Naunyn Schmiedebergs Arch Pharmacol 2005;372:195-202. (Pubitemid 41668749)
29. Barr AM, Lehmann-Masten V, Paulus M, et al. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 2004;29:221-228 (Pubitemid 38175141)
30. Wadenberg MG, Browning JL, Young KA, et al. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 2001;68:363-370
31. Egbe P, Engel J, Gustafsson B, et al. Amperozide and conditioned behaviour in rats: potentiation by classical neuroleptics and alphamethylparatyrosine. Pharmacol Toxicol 1990;66(Suppl 1):18-21. (Pubitemid 20096819)
32. Barr AM, Powell SB, Markou A, et al. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 2006;51:457-465 (Pubitemid 44215953)
33. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008;172:177-197
34. Huang M, Li Z, Ichikawa J, et al. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex. Brain Res 2006;1099:44-55. (Pubitemid 44080087)
35. Ichikawa J, Chung YC, Dai J, et al. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Res 2005;1052:56-62. (Pubitemid 41116287)
36. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-262 (Pubitemid 30609659)
37. Ago Y, Sato M, Nakamura S, et al. Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex. J Pharmacol Sci 2006;102:419-422 (Pubitemid 44954602)
38. Liegeois JF, Ichikawa J, Meltzer HY. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 2002;947:157-165 (Pubitemid 34899500)
39. Snigdha S, Thumbi C, Reynolds GP, et al. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 2008;22:567-571
40. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293 (Pubitemid 29077120)
41. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine D(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001;158:311-314 (Pubitemid 32116532)
42. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994;55(suppl B):78-81. (Pubitemid 24353023)
43. Gaebel W, Weinmann S, Sartorius N, et al. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005; 187:248-255 (Pubitemid 41306106)
44. Addington D, Bouchard R-H, Goldberg J, et al. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005;(50 Suppl 1):1S-56S.
45. Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007;92:90-94 (Pubitemid 46561216)
46. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. Br J Psychiatry 1997;171:569-573
47. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482 (Pubitemid 43200298)
48. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-136 (Pubitemid 40095682)
49. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.
50. Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008;41:24-28 (Pubitemid 351195889)
51. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-731 (Pubitemid 351838681)
52. Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol 2009;23:305-314
53. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009;119:419-425
54. Barbui C, Signoretti A, Mulè S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35:458-468
55. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20:409-415 (Pubitemid 41318007)
56. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Risperidone augmentation of clozapine: a critical review. Eur Arch Psychiatry Clin Neurosci 2006;256:350-355
57. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 2007;27:198-204. (Pubitemid 46594939)
58. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-457
59. Pickar D, Bartko JJ. Effect size of symptom status in withdrawal of typical antipsychoticcs and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. Am J Psychiatry 2003;160:1133-1138 (Pubitemid 41070973)
60. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
61. Remington G, Saha A, Chong SA, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:843-872
62. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One 2008;3:e3150.
63. Rittmannsberger H. The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:547-551 (Pubitemid 34252949)
64. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57:1094-1101
65. Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry 2006;67:1261-1265 (Pubitemid 44439699)
66. Centorrino F, Cincotta SL, Talamo A, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008;49:65-69 (Pubitemid 350183965)
67. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009;109:10-14
68. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007;27:582-589 (Pubitemid 351339444)
69. Moore TA, Covell NH, Essock SM. World antipsychotic treatment practices. Psychiatr Clin North Am 2007;30:401-416
70. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. Acta Psychiatr Scand 2002;106:323-330
71. Broekema WJ, de Groot IW, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics - a European study. Pharm World Sci 2007;29:126-130 (Pubitemid 46872979)
72. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007;58:489-495 (Pubitemid 46640639)
73. Taylor DM. Prescribing of clozapine and olanzapine: dosage, polypharmacy and patient ethnicity. Psychiatr Bull R Coll Psychiatr 2004;28:241-243
74. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41-48 (Pubitemid 36192948)
75. Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007;58:1007-1010
76. Kreyenbuhl J, Valenstein M, McCarthy JF, et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 2006;84:90-99 (Pubitemid 43732483)
77. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26. (Pubitemid 41460700)
78. Patrick V, Schleifer SJ, Nurenberg JR, et al. An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006;57:21-23 (Pubitemid 43053830)
79. Kogut SJ, Yam F, Dufresne R. Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm 2005;11:17-24.
80. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 2002;28:31-42.
81. Wang PS, West JC, Tanielian T, et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000;26:451-457 (Pubitemid 30423221)
82. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001;39:923-933
83. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 2000;15:220-226 (Pubitemid 30350559)
84. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28:17-29.
85. Yip KC, Ungvari GS, Cheung HK, et al. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J 1997;110:792-796 (Pubitemid 27443738)
86. Centorrino F, Eakin M, Bahk W-M, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002;159:1932-1935
87. Brunot A, Lachaux B, Sontag H, et al. Pharmaco-epidemiological study on antipsychotic drug prescription in french psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 2002;28:129-138 (Pubitemid 34627315)
88. Biancosino B, Barbui C, Marmai L, et al. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 2005;20:305-309 (Pubitemid 41475319)
89. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005;187:243-247 (Pubitemid 41306105)
90. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75-84.
91. Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999;14:33-40. (Pubitemid 30700515)
92. Barbui C, Biancosino B, Esposito E, et al. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 2007;22:221-225 (Pubitemid 46801945)
93. Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics. Part 1: risk factors and mechanisms. Adv Psychiatr Treat 2006; 12:35-44. (Pubitemid 43091931)
94. Chong SA, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull 2000;26:421-440
95. Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-127
96. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-329 (Pubitemid 28454819)
97. Henderson DC, Goff DC, Connolly CE, et al. Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001;62:605-608
98. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397 (Pubitemid 26321990)
99. Akdede BB, Anil Yagcioglu AE, Alptekin K, et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006;67:1912-1919 (Pubitemid 46048188)
100. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005;21:2017-2028
101. Knapp M. Costs of schizophrenia. Psychiatry Res 2005;4:33-35
102. Ohlsen RI, Taylor D, Tandon K, et al. Returning to the issue of the cost-effectiveness of antipsychotics in the treatment of schizophrenia. Clin Neuropsychiatry 2008;5:184-194
103. Essock SM, Frisman LK, Covell NH, et al. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000;57:987-994
104. Drew LR, Griffiths KM, Hodgson DM. A five year follow-up study of the use of clozapine in community practice. Aust N Z J Psychiatry 2002;36:780-786
105. Davies LM, Barnes TR, Jones PB, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health 2008;11:549-562
106. Zhu B, Ascher-Svanum H, Faries DE, et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008;8:19. (Pubitemid 351622429)
107. Rupnow MF, Greenspan A, Gharabawi GM, et al. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 2007;23:2815-2822 (Pubitemid 350146419)
108. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 2006;57:127-129
109. Valuck RJ, Morrato EH, Dodd S, et al. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. Curr Med Res Opin 2007;23:2567-2576 (Pubitemid 350033459)
110. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: casecontrol study of risks versus benefits. Am J Psychiatry 2004;161:700-706 (Pubitemid 38445515)
111. Carr VJ, Neil AL, Halpin SA, et al. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003;37:31-40.
112. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-345
113. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
114. Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-516 (Pubitemid 38725711)
115. Ayuso-Gutiérrez JL, del Río Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206. (Pubitemid 28055667)
116. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
117. Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009;2:6.
118. Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 2008;42:852-860
119. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003;64:30-34 (Pubitemid 36182226)
120. Chong SA, Remington GJ, Bezchlibnyk-Butler KZ. Effect of clozapine on polypharmacy. Psychiatr Serv 2000;51:250-252
121. Nasrallah HA, Keshavan MS, Benes FM, et al. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. J Clin Psychiatry 2009;70(S1):4-46.
122. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, et al. Medicine. Life cycle of translational research for medical interventions. Science 2008;321:1298-1299
123. Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006;20:86-90.
124. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008;22:49-68.
125. Lee TH. Eulogy for a quality measure. N Engl J Med 2007;357:1175-1177
126. Naik AD, Petersen LA. The neglected purpose of comparative-effectiveness research. N Engl J Med 2009;360:1929-1931
127. Alegria M. AcademyHealth 25th Annual Research Meeting chair address: from a science of recommendation to a science of implementation. Health Serv Res 2009;44:5-14.
128. Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA 2008;300:2177-2179
129. Mercer SL, DeVinney BJ, Fine LJ, et al. Study designs for effectiveness and translation research:identifying trade-offs. Am J Prev Med 2007;33:139-154